NeuraWorx Medical Technology, a company focused on neurotechnology, has completed an oversubscribed seed funding round led by Nexus NeuroTech Ventures. The funding attracted participation from Foothill Ventures, Verge HealthTech Fund, and the Wisconsin Alumni Research Foundation, among others. NeuraWorx is working on innovative bioelectronic solutions to address cerebrovascular and glymphatic dysfunction, which are linked to various neurodegenerative and neuropsychiatric conditions. John Propst of Nexus NeuroTech highlighted the strong scientific foundation and clinical potential of NeuraWorx’s approach. With the new funding, NeuraWorx plans to expand its team and accelerate the development of its Cerebrovascular Pacing System™, aiming to bring this technology to patients swiftly and safely.
Has NeuraWorx successfully closed its oversubscribed seed funding round?
